Sam Brusco, Associate Editor09.13.23
Aurora Spine began full commercial rollout of its SiLO TFX MIS (minimally invasive surgical) sacroiliac joint fixation system.
SiLO TFX is indicated for sacroiliac joint fusion for conditions that include sacroiliac joint disruptions and degenerative sacroiliitis. The system is comprised of a transfixing-cone, ilium screw, sacrum screw, and accompanying instrumentation.
Aurora Spine said SiLO TFX implants are designed to transfix the sacrum and ilium to offer stability for bony fusion. The company completed the first surgeries using SiLO TFX earlier this year.
Trent Northcutt, Aurora’s president, CEO, and co-founder, told the press, "We are excited to be in full launch of our game changing treatment for patients suffering with SI Joint pain and disfunction.”
Petra Lopizzo, Aurora’s director of operations, added, “The release of SiLO TFX is proceeding smoothly and rapidly as we deploy more instruments sets and implants into the field. I am pleased with the teamwork between Engineering, Operations and Marketing on the full release of the SiLO TFX system."
In June, the company began its multicenter study of the DEXA-C cervical interbody system by enrolling the first patient. DEXA-C is a line of cervical cages that gained U.S. Food and Drug Administration (FDA) 510(k) clearance for anterior cervical discectomy with fusion (ACDF) surgeries in August 2021.
SiLO TFX is indicated for sacroiliac joint fusion for conditions that include sacroiliac joint disruptions and degenerative sacroiliitis. The system is comprised of a transfixing-cone, ilium screw, sacrum screw, and accompanying instrumentation.
Aurora Spine said SiLO TFX implants are designed to transfix the sacrum and ilium to offer stability for bony fusion. The company completed the first surgeries using SiLO TFX earlier this year.
Trent Northcutt, Aurora’s president, CEO, and co-founder, told the press, "We are excited to be in full launch of our game changing treatment for patients suffering with SI Joint pain and disfunction.”
Petra Lopizzo, Aurora’s director of operations, added, “The release of SiLO TFX is proceeding smoothly and rapidly as we deploy more instruments sets and implants into the field. I am pleased with the teamwork between Engineering, Operations and Marketing on the full release of the SiLO TFX system."
In June, the company began its multicenter study of the DEXA-C cervical interbody system by enrolling the first patient. DEXA-C is a line of cervical cages that gained U.S. Food and Drug Administration (FDA) 510(k) clearance for anterior cervical discectomy with fusion (ACDF) surgeries in August 2021.